Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Rashad
 
NCT04519385
RCTdexamethasonetocilizumab COVID-19 severe or criticallyhigh
75/74 suggested
  • suggested 54 % decrease in deaths,deaths (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
  • suggested 65 % decrease in death D28 but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).